使用する絶縁マウスハーツの心機能およびエネルギー論の評価 ³¹ P NMR分光法

Executive Industry Relevance

This protocol enables simultaneous assessment of cardiac function and energetics in isolated mouse hearts, providing a physiologically relevant system for evaluating molecular modifications in cardiovascular disease models. By integrating Langendorff perfusion with ³¹P NMR spectroscopy, researchers can obtain real-time, quantitative readouts of high-energy phosphate metabolites alongside hemodynamic parameters, supporting mechanistic de-risking in target validation and preclinical screening workflows. The approach enhances predictive confidence by linking molecular alterations to functional and metabolic phenotypes in a disease-relevant system.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by measuring how genetic or pharmacological interventions affect cardiac energetics and function in intact, beating hearts.
• Operational Value: Enables functional target validation through simultaneous monitoring of LV developed pressure and phosphocreatine/ATP levels under physiological or pathologic stress.
• Predictive Value: Supports portfolio triage by identifying compounds or genetic modifications that preserve energetic homeostasis during ischemia/reperfusion or high-workload challenges.

Screening & Assay Development

• Assay Readiness: Prepares validated biological systems for downstream compound screening by establishing baseline cardiac function and metabolite levels in a reproducible, Langendorff-perfused format.
• Quantitative Outputs: Generates simultaneous, real-time measurements of hemodynamic function (LV pressure) and biochemical energetics (PCr, ATP, Pi) for multi-parametric assay development.
• Scalability & Reuse: The isolated heart platform can be adapted across disease models (e.g., aortic banding, transgenic models) to enable consistent, cross-project evaluation of cardiac safety and efficacy signals.

Translational & Preclinical Research

• Disease Relevance: Directly assesses the functional and energetic significance of molecular modifications in transgenic models of cardiac pathology, supporting translational biomarker alignment.
• Preclinical Continuity: Bridges discovery-phase target validation with preclinical evaluation by providing a quantitative, physiologically anchored readout of cardiac health.
• Risk-Adjusted Decisions: Informs go/no-go criteria by detecting early energetic dysfunction that may predict late-stage clinical failure in cardiovascular programs.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead optimization to preclinical assessment, offering a reusable platform for evaluating cardiac liability and target engagement in disease-relevant systems.

• Discovery Biology: Supports hypothesis testing and pathway clarification by linking genetic or pharmacological perturbations to measurable changes in cardiac energetics and contractile function.
• Screening: Enables assay standardization and reproducibility through controlled perfusion conditions, real-time pressure monitoring, and consistent NMR spectral acquisition.
• Analytics: Delivers quantitative, multi-parametric readouts (LV developed pressure, end-diastolic pressure, PCr/ATP ratios, Pi shifts) that allow objective comparison across experimental conditions and compound treatments.
• Translational Research: Connects early discovery to preclinical validation by maintaining physiological relevance while enabling biochemical interrogation of metabolic pathways in intact hearts.
• Enterprise Reuse: Represents a scalable, cross-functional capability applicable to cardiovascular, metabolic, and mitochondrial toxicity programs across multiple therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by correlating molecular changes with direct measurements of cardiac function and high-energy phosphate metabolism.
• Operational Value: Ensures reproducibility through standardized buffer preparation, temperature control, pressure transducer calibration, and NMR shimming procedures.
• Strategic Value: Improves capital efficiency by identifying cardiotoxic or metabolically disruptive compounds early, reducing late-stage attrition in cardiovascular drug development.
• Portfolio Impact: Enables risk-based prioritization of targets and leads by providing early insight into energetic reserve and stress resilience in disease models.

Implementation Considerations

• Requires expertise in isolated heart perfusion, NMR spectroscopy, and pressure transducer calibration.
• Dependent on access to high-field NMR spectrometers (e.g., 14T) and specialized perfusion hardware compatible with magnet bore constraints.
• Necessitates cross-team standardization between physiology, pharmacology, and NMR analytics teams for consistent data acquisition and interpretation.
• Adaptation considerations include model-specific adjustments to perfusion pressure, balloon volume, and substrate composition based on disease phenotype or genetic background.
• Practical limitations include signal-to-noise constraints in low-abundance metabolite detection and the need for rigorous exclusion of ischemic artifacts during setup.

Biopharma FAQs